ESMO Breast 2022 | The significance of HER2 expression for the activity of trastuzumab deruxtecan

Maria Fernanda Mosele, MD, Gustave Roussy, Villejuif, France, talks on the significance of HER2 expression for the activity of trastuzumab deruxtecan (T-DXd), noting on a significant difference in TDX-D distribution in tumor according to HER2 expression. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.